Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Amyris Inc AMRSQ

Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Company’s sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.


GREY:AMRSQ - Post by User

<< Previous
Bullboard Posts
Next >>
Post by jthottamon Dec 18, 2021 2:12am
369 Views
Post# 34242933

IDRI Contract with BARDA (potential opportunity for AMRS)

IDRI Contract with BARDA (potential opportunity for AMRS)
Update: Amyris (Ticker: AMRS)
 
The following was published by Infection Disease Research Institue ("IDRI") whom AMRS has an exclusive license for an RNA vaccine platform.
 
https://www.idri.org/wp-content/uploads/2021/12/IDRI-BARDA-Award-Release_12.14.21.pdf
 
The Biomedical Advanced Research and Development Authority ("BARDA"), a U.S. Department of Health and Human Services office responsible for the procurement and development of medical countermeasures, has contracted with IDRI to develop an intranasally delivered RNA vaccine for pandemic influenza.
 
While the piece does not specifically mention AMRS, we do know AMRS was previously involved with intranasal delivered RNA research and AMRS also can provide the adjuvent for lower cost and sustainable manufacturing for the vaccine.
 
While this is a 2 year contract with IDRI, I suspect this is another seed of opportunity/optionality for AMRS further down the road.
 
If you like this and other research, feel free to follow me at:

Stock Talk with In the Ruff Research | Facebook
 
Happy Holidays and Happy Investing!

<< Previous
Bullboard Posts
Next >>